Log in or register to see all Alerts
New HTA Decisions in England
September 2020
Drug name
SOLIRIS® (eculizumab)
Company
Alexion Pharma UK
Decision date
//
Therapeutic area
Blood and immune system conditions
Therapeutic sub area
Blood and immune system conditions: general and other
Decision
Not recommended
Indication
Relapsing neuromyelitis optica (terminated appraisal).
Decision Detail
This was a terminated appraisal.
Summary
NICE was unable to make a recommendation on eculizumab (Soliris) for treating relapsing neuromyelitis optica because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission. The company has confirmed that it does not intend to make a submission for the appraisal because the technology will not be launched in the UK for this indication.